With its Research and Development sites located in different continents worldwide, Ceva is committed to develop innovative vaccines that can meet the current needs; to ensure animals’ health...

Ceva’s background and continuous work in biological products provides excellency in the prevention of cattle diseases:

  • COGLAVAX® / COGLAVAX® S (clostridiosis): a vaccine that contains several different clostridial antigens in one single dose. Clostridial pathogens are ubiquitous and cattle are at risk to suffer from clostridial diseases during most part of their lives.
  • COXEVAC® (coxiellosis or Q fever): a vaccine to protect against Q fever. This disease causes significant reproductive losses in both cattle and small ruminants. Moreover, it is a zoonosis therefore humans can be infected and suffer from the disease too. It has the advantage of being a so-called "phase 1" vaccine which, when used for prevention, not only minimizes the disease’s clinical impact, but also considerably reduces or even eliminates bacteria excretion in vaccinated animals, thereby limiting contamination of the external environment.
  • MUCOSIFFA® (BVD): a vaccine with a long presence in the market. It assures its efficacy and safety in the control of BVD in cattle. With 12 months duration of immunity it provides active immunization against transplacental BVD infection of the foetus and prevents the viremia caused by infection by BVD virus.
  • AFTOMUNE® (FMD): a vaccine indicated for the prevention of foot-and-mouth disease (FMD), developed on top of the highest and most rigorous quality and safety standards, so the protection of the vaccinated herd is assured.



From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top